outbreak
middl
east
respiratori
syndrom
mer
worldwid
current
novel
human
coronaviru
caus
major
diseas
outbreak
name
corona
viru
diseas
emerg
mrescov
caus
global
panic
threaten
health
secur
unfortun
similar
differ
two
coronaviru
diseas
remain
unknown
aim
studi
therefor
perform
systemat
review
compar
epidemiolog
clinic
laboratori
featur
merscov
popul
search
pubm
embas
cochran
regist
control
trial
databas
identifi
potenti
studi
report
merscov
epidemiolog
clinic
laboratori
outcom
admiss
rate
intens
cure
unit
icu
discharg
rate
fatal
rate
evalu
use
graphpad
prism
softwar
thirtytwo
studi
involv
patient
merscov
includ
studi
present
studi
reveal
compar
popul
merscov
popul
higher
rate
icu
admiss
discharg
fatal
longer
incub
time
point
fever
cough
generalis
weak
myalgia
main
clinic
manifest
merscov
wherea
ard
main
complic
effect
drug
merscov
ribavirin
interferon
coronavirus
rna
virus
envelop
nonseg
positivesens
caus
respiratori
intestin
tract
infect
human
mammal
despit
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
although
mani
previou
studi
report
clinic
characterist
merscov
diseas
systemat
comparison
clinic
featur
merscov
diseas
yet
publish
thu
purpos
studi
perform
systemat
review
epidemiolog
clinic
laboratori
characterist
patient
infect
merscov
diseas
compar
merscov
context
incub
laboratori
featur
admiss
rate
intens
cure
unit
icu
rate
discharg
fatal
provid
comprehens
refer
clinic
physician
treatment
coronaviru
diseas
comprehens
systemat
search
perform
use
pubm
embas
novel
coronaviru
necessari
also
contact
correspond
author
obtain
accur
data
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
studi
met
follow
criteria
includ
report
clinic
characterist
merscov
diseas
minimum
sampl
size
five
confirm
merscov
diseas
english
literatur
studi
exclud
follow
criteria
duplic
public
case
report
metaanalysi
letter
review
technolog
report
commentari
anim
trial
correspond
predict
studi
guidenc
radiograph
studi
meet
report
begin
potenti
public
identifi
remov
duplic
review
titl
abstract
remain
public
public
exclud
follow
reason
involv
research
point
n
review
n
english
n
case
report
n
metaanalysi
n
letter
n
technolog
report
n
commentari
n
anim
studi
n
correspond
n
predict
studi
n
guidenc
n
meet
report
n
radiograph
n
comprehens
review
fulltext
conduct
remain
public
two
review
independ
screen
elig
literatur
argument
solv
discuss
third
review
final
thirtytwo
studi
includ
studi
process
shown
figur
two
review
extract
independ
common
clinic
laboratori
characterist
includ
studi
disagr
solv
discuss
third
review
extract
data
includ
incub
time
white
blood
cell
wbc
count
lymphocyt
count
creactiv
protein
crp
alamin
aminotransferas
alt
aspart
aminotransferas
ast
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
creatinin
creatin
kinas
ck
admiss
rate
intens
cure
unit
icu
rate
discharg
fatal
symptom
comorbid
complic
cure
rate
drug
normal
distribut
data
outcom
extract
directli
skew
distribut
data
outcom
extract
convert
specif
formula
qualiti
assess
includ
studi
perform
newcastleottawa
qualiti
assess
scale
no
recommend
cochran
nonrandom
studi
no
includ
three
part
risk
bia
nine
point
total
select
research
group
four
point
intergroup
compar
two
point
ascertain
exposur
outcom
three
point
casecontrol
cohort
studi
respect
studi
score
qualifi
systemat
review
assess
process
complet
two
review
independ
debat
solv
discuss
third
review
statist
analys
graph
gener
plot
use
graphpad
prism
version
softwar
graphpad
softwar
inc
p
valu
suggest
signific
differ
includ
studi
retrospect
studi
among
ten
studi
report
one
trial
perform
netherland
remain
nine
trial
conduct
china
sampl
size
rang
total
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
one
trial
perform
iran
one
trial
conduct
japan
sampl
size
rang
total
patient
year
public
rang
clinic
laboratori
characterist
includ
studi
shown
tabl
tabl
respect
among
thirtytwo
includ
studi
four
studi
obtain
point
no
remain
twentyeight
studi
obtain
point
no
result
qualiti
assess
present
tabl
popul
number
patient
fever
cough
generalis
weak
myalgia
stuffi
rhinorrhoea
pharyngalgia
chest
pain
diarrhoea
anorexia
dyspnoea
dizzi
headach
merscov
popul
amount
patient
fever
cough
generalis
weak
myalgia
stuffi
rhinorrhoea
pharyngalgia
chest
pain
diarrhoea
anorexia
dyspnoea
dizzi
headach
result
shown
tabl
popul
main
complic
includ
shock
arrhythmia
acut
respiratori
distress
syndrom
ard
acut
cardiac
injuri
acut
kidney
injuri
acut
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
liver
injuri
amount
respect
merscov
popul
number
individu
present
shock
arrhythmia
ard
acut
cardiac
injuri
acut
kidney
injuri
acut
liver
injuri
neurolog
symptom
result
shown
tabl
tabl
systemat
review
perform
clinic
laboratori
outcom
coronaviru
diseas
signific
differ
age
vs
p
wbc
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
higher
admiss
rate
icu
found
merscov
popul
popul
vs
figur
higher
discharg
rate
merscov
popul
compar
popul
vs
figur
lower
fatal
rate
found
popul
compar
merscov
popul
vs
figur
coronaviru
import
pathogen
caus
respiratori
intestin
infect
seven
identifi
coronavirus
two
pathogen
virus
sarscov
merscov
caus
sever
ard
even
acut
respiratori
failur
mortal
rate
respect
four
human
coronavirus
addit
found
number
male
femal
either
merscov
popul
possibl
reason
reduc
suscept
femal
viral
infect
femal
lot
x
chromosom
estrogen
vital
compon
develop
innat
adapt
immun
meanwhil
number
patient
infect
chronic
comorbid
mainli
hypertens
diabet
cardiovascular
diseas
similar
merscov
popul
result
indic
older
adult
male
chronic
underli
diseas
might
suscept
merscov
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
term
laboratori
test
reduc
lymphocyt
increas
crp
found
merscov
patient
result
indic
might
associ
cellular
immun
respons
mainli
act
lymphocyt
like
merscov
cell
infect
virus
induc
releas
number
proinflammatori
cytokin
inflamm
storm
bodi
moreov
increas
cytokin
might
make
damag
relat
organ
liver
result
demonstr
abnorm
valu
ast
found
merscov
popul
popul
possibl
reason
followup
time
popul
short
liver
might
remain
compensatori
stage
result
long
followup
time
studi
urgent
need
hand
result
suggest
merscov
popul
higher
rate
icu
admiss
fatal
popul
indic
compar
merscov
less
toxic
easili
cure
howev
lower
discharg
rate
found
covid
popul
merscov
popul
possibl
explan
patient
remain
hospit
time
manuscript
submiss
data
patient
could
obtain
time
thu
care
interpret
urg
result
effect
strategi
found
treatment
infect
current
measur
control
sourc
infect
take
person
protect
work
reduc
risk
transmiss
earli
diagnos
isol
support
treat
confirm
patient
present
studi
systemat
result
cure
rate
drug
merscov
infect
indic
ribavirin
interferon
oseltamivir
antivir
intraven
immunoglobulin
effect
merscov
infect
cure
rate
drug
respect
thu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
assum
drug
might
also
effect
infect
howev
studi
need
confirm
idea
studi
sever
limit
first
mani
patient
infect
remain
hospit
time
manuscript
submiss
lead
unavail
data
second
followup
time
popul
short
get
relat
data
longterm
observ
diseas
third
find
statist
test
p
valu
merscov
popul
interpret
caution
fourth
number
merscov
patient
treat
drug
small
care
understand
need
cure
rate
drug
diseas
final
still
develop
around
world
remain
mani
unknown
result
studi
stage
need
care
understood
largesampl
multicentr
highqual
research
perform
updat
studi
systemat
review
reveal
main
clinic
manifest
merscov
popul
fever
cough
generalis
weak
myalgia
ard
main
complic
two
popul
popul
shorter
incub
time
lower
rate
icu
admiss
discharg
fatal
compar
mrescov
popul
studi
support
grant
nation
natur
scienc
foundat
china
guangzhou
municip
scienc
technolog
project
no
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
